AGM
ATRA icon

Alpine Global Management’s Atara Biotherapeutics ATRA Stock Holding History

Alpine Global Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,419
Closed -$116K – 165
2022
Q4 		$116K Buy
+1,419
New +$148K 0.04% 193

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Alpine Global Management's ATRA Position: Q1 2023 in Review

Alpine Global Management sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 1,419 shares — an estimated $116K sold.

Alpine Global Management first reported a position in ATRA in Q4 2022 and held it in 1 quarter. The position peaked at $116K in Q4 2022. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

  • Alpine Global Management reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 1,419 Atara Biotherapeutics shares in Q1 2023, an estimated $116K.
  • Alpine Global Management first reported a position in Atara Biotherapeutics in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Atara Biotherapeutics position peaked at $116K in Q4 2022.
  • 125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.